v3.26.1
Segment Information - Schedule of Significant Segment Expenses and Segment Operating Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting [Abstract]            
Revenues $ 0 $ 0 $ 0 $ 0 $ 0 $ 0
Research and Development Expense [Abstract]            
Compensation and related expenses 5,486 [1] 7,067 [1] 10,734 [1] 13,156 [1] 21,828 [2] 24,537 [2]
Drug discovery and platform 51 [1] 417 [1] 249 [1] 567 [1] 1,026 [2] 844 [2]
Clinical and manufacturing activities 12,637 [1] 12,428 [1] 20,448 [1] 24,447 [1] 52,065 [2] 36,831 [2]
Occupancy and all other costs 2,687 [1] 1,872 [1] 4,482 [1] 3,915 [1] 7,461 [2] 8,037 [2]
Total research and development expense 20,861 21,784 35,913 42,085 82,380 70,249
General and Administrative Expense [Abstract]            
Compensation and related expenses 2,096 [3] 2,228 [3] 4,359 [3] 4,576 [3] 8,174 [4] 7,912 [4]
Consulting and professional services 1,244 [3] 1,010 [3] 2,441 [3] 2,249 [3] 4,382 [4] 4,791 [4]
Occupancy and all other costs 387 [3] 475 [3] 701 [3] 1,081 [3] 1,800 [4] 1,243 [4]
Total general and administrative expense 3,727 3,713 7,501 7,906 14,356 13,946
Stock-based compensation 1,552 2,762 3,006 4,871 8,931 7,060
Other segment items [5] (276) (1,363) (923) (2,980) (5,060) (8,146)
Net loss $ 25,864 $ 26,896 $ 45,497 $ 51,882 $ (100,607) $ (83,109)
[1] Research and development expense excludes stock-based compensation expense, which is presented separately below. Stock-based compensation expense excluded from research and development expense was $0.7 million and $1.2 million for the three months ended June 30, 2026 and 2025, respectively, and $1.4 million and $2.0 million for the six months ended June 30, 2026 and 2025, respectively.
[2] Research and development expense for the years ended December 31, 2025 and 2024 exclude $3.7 million and $2.9 million of stock-based compensation expense, respectively, which is presented separately below.
[3] General and administrative expense excludes stock-based compensation expense, which is presented separately below. Stock-based compensation expense excluded from general and administrative expense was $0.8 million and $1.6 million for the three months ended June 30, 2026 and 2025, respectively, and $1.6 million and $2.9 million for the six months ended June 30, 2026 and 2025, respectively.
[4] General & administrative expense for the years ended December 31, 2025 and 2024 exclude $5.2 million and $4.1 million of stock-based compensation expense, respectively, which is presented separately below.
[5] Other segment items include interest and other income, net.